Assessing the Utility of Peak Inspiratory Flow as a Predictor for COPD Exacerbations (PIF in COPD)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/47924
• EU PAS number:
  EUPAS34689
• Study ID:
  47924
• Official title and acronym:
  Assessing the Utility of Peak Inspiratory Flow as a Predictor for COPD Exacerbations (PIF in COPD)
• DARWIN EU® study:
  No
• Study countries:
  Denmark

  Italy

  Korea, Republic of

  Malta

  Poland

  Singapore

  Slovenia

  Spain
• Study description:
  This is an international, mulitcentre, observational, prospective study into Peak Inspiratory Flow in COPD patients that aims to: A) Determine the prevalence of suboptimal Peak Inspiratory Flow (PIF) and inadequate inhaler choice and assess the baseline characteristics of these groups. B) Assess the clinical role of PIF and inhaler choice in predicting COPD exacerbations and symptom burden. C) Assess the variability and correlation of PIF with other lung function measurements and CAT score in stable COPD. It is a 12 month study comprising one baseline assessment and 2 follow-up visits at 6 and 12 months.
• Study status:
  Ongoing

Research institution and networks

Institutions

Respiratory Effectiveness Group

Networks

Respiratory Effectiveness Group (REG)

Belgium

Denmark

France

Germany

Greece

Hungary

Italy

Netherlands

Spain

Sweden

United Kingdom

Study timelines

Date when funding contract was signed

Planned: 10/03/2020

Actual: 10/03/2020

Study start date

Planned: 30/09/2020

Actual: 05/11/2020

Date of final study report

Planned: 30/04/2024

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable